Medisa Shinyaku

Medisa Shinyaku was a Japanese pharmaceutical company specializing in the development, manufacturing, and sale of generic drugs. As a subsidiary of Sawai Pharmaceutical, it contributed to the group's extensive portfolio of affordable medications across various therapeutic areas, including cardiovascular, metabolic, and central nervous system disorders. The company operated manufacturing facilities and focused on ensuring a stable supply of high-quality generic medicines in the Japanese market. In April 2023, Medisa Shinyaku was officially merged into its parent company, Sawai Pharmaceutical, to streamline operations and enhance the group's supply chain efficiency.